PapersPMID:37667938
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.
- 01 · findings
- 3
- 02 · compound
- 1
- 03 · endpoints
- 3
- 04 · null
- 0
What it reported
How to read these marksWhat moved
3 findings
calciol — decreases alanine aminotransferase
Evidence strength: very limited.Finding“Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results.”
Quoted verbatim from A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.. - Study
- RCT
- Population
- NAFLD patients with type 2 diabetes on standard conventional therapy in both arms; cholecalciferol added in Group 2 vs placebo added in Group 1
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.2023PMID:3766793810.26355/eurrev_202308_33413Permalink
calciol — decreases malondialdehyde (circulating)
Evidence strength: very limited.Finding“Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results.”
Quoted verbatim from A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.. - Study
- RCT
- Population
- NAFLD patients with type 2 diabetes on standard conventional therapy in both arms; cholecalciferol added in Group 2 vs placebo added in Group 1
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.2023PMID:3766793810.26355/eurrev_202308_33413Permalink
calciol — decreases C-reactive protein concentration
Evidence strength: very limited.Findingreplicated ×2“Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results.”
Quoted verbatim from A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.. - Study
- RCT
- Population
- NAFLD patients with type 2 diabetes on standard conventional therapy in both arms; cholecalciferol added in Group 2 vs placebo added in Group 1
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.2023PMID:3766793810.26355/eurrev_202308_33413Permalink
Study record
Read under: calciol
- Design
- randomised controlled trial
- Species
- human
- Population
- NAFLD patients with type 2 diabetes on standard conventional therapy in both arms; cholecalciferol added in Group 2 vs placebo added in Group 1
- Participants
- not recorded
- Comparator
- not stated in the paper
- Duration
- 120 days
- Endpoints
- 7
- Record
- extracted
- Readings recorded
- 2